Abstract
Pediatric solid and central nervous system tumors are the leading cause of cancer-related death among children. Identifying new targeted therapies necessitates the use of pediatric cancer models that faithfully recapitulate the patient's disease. However, the generation and characterization of pediatric cancer models has significantly lagged behind adult cancers, underscoring the urgent need to develop pediatric-focused cell line resources. Herein, we establish a single-site collection of 261 cell lines, including 224 pediatric cell lines representing 18 distinct extracranial and brain childhood tumor types. We subjected 182 cell lines to multi-omics analyses (DNA sequencing, RNA sequencing, DNA methylation), and in parallel performed pharmacological and genetic CRISPR-Cas9 loss-of-function screens to identify pediatric-specific treatment opportunities and biomarkers. Our work provides insight into specific pathway vulnerabilities in molecularly defined pediatric tumor classes and uncovers biomarker-linked therapeutic opportunities of clinical relevance. Cell line data and resources are provided in an open access portal.
Original language | English |
---|---|
Pages (from-to) | 660-677.e7 |
Number of pages | 26 |
Journal | Cancer Cell |
Volume | 41 |
Issue number | 4 |
DOIs | |
Publication status | Published - 10 Apr 2023 |
Keywords
- biomarker
- brain cancer
- cell line atlas
- CRISPR screens
- epigenetics
- machine learning
- multi-omics feature analysis
- pediatric cancers
- precision medicine
- targeted therapy
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Cancer Cell, Vol. 41, No. 4, 10.04.2023, p. 660-677.e7.
Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities
AU - Sun, Claire Xin
AU - Daniel, Paul
AU - Bradshaw, Gabrielle
AU - Shi, Hui
AU - Loi, Melissa
AU - Chew, Nicole
AU - Parackal, Sarah
AU - Tsui, Vanessa
AU - Liang, Yuqing
AU - Koptyra, Mateusz
AU - Adjumain, Shazia
AU - Sun, Christie
AU - Chong, Wai Chin
AU - Fernando, Dasun
AU - Drinkwater, Caroline
AU - Tourchi, Motahhareh
AU - Habarakada, Dilru
AU - Sooraj, Dhanya
AU - Carvalho, Diana
AU - Storm, Phillip B.
AU - Baubet, Valerie
AU - Sayles, Leanne C.
AU - Fernandez, Elisabet
AU - Nguyen, Thy
AU - Pörksen, Mia
AU - Doan, Anh
AU - Crombie, Duncan E.
AU - Panday, Monty
AU - Zhukova, Nataliya
AU - Dun, Matthew D.
AU - Ludlow, Louise E.
AU - Day, Bryan
AU - Stringer, Brett W.
AU - Neeman, Naama
AU - Rubens, Jeffrey A.
AU - Raabe, Eric H.
AU - Vinci, Maria
AU - Tyrrell, Vanessa
AU - Fletcher, Jamie I.
AU - Ekert, Paul G.
AU - Dumevska, Biljana
AU - Ziegler, David S.
AU - Tsoli, Maria
AU - Syed Sulaiman, Nur Farhana
AU - Loh, Amos Hong Pheng
AU - Low, Sharon Yin Yee
AU - Sweet-Cordero, E. Alejandro
AU - Monje, Michelle
AU - Resnick, Adam
AU - Jones, Chris
AU - Downie, Peter
AU - Williams, Bryan
AU - Rosenbluh, Joseph
AU - Gough, Daniel
AU - Cain, Jason E.
AU - Firestein, Ron
N1 - Funding Information: We thank Monash Health and Royal Children’s Hospital Pathology staff for assistance in tissue allocation, Dr. David Eisenstat for helpful discussion, Mr. Yuankun Zhu for data analysis, Ms. Steph Forman for editing assistance, and Mr. Ethan Newnham for annotation of BBB penetration. Funding for this project was generously provided by the Children’s Cancer Foundation, Australia , Robert Connor Dawes Foundation , and the Medical Research Future Fund ( NHMRC Project 2007620 ). We thank over 30 contributing sites for providing cell lines and/or tissues from which cell lines were generated. A full list of cell line contributors is provided in the supplemental information . Funding Information: We thank Monash Health and Royal Children's Hospital Pathology staff for assistance in tissue allocation, Dr. David Eisenstat for helpful discussion, Mr. Yuankun Zhu for data analysis, Ms. Steph Forman for editing assistance, and Mr. Ethan Newnham for annotation of BBB penetration. Funding for this project was generously provided by the Children's Cancer Foundation, Australia, Robert Connor Dawes Foundation, and the Medical Research Future Fund (NHMRC Project 2007620). We thank over 30 contributing sites for providing cell lines and/or tissues from which cell lines were generated. A full list of cell line contributors is provided in the supplemental information. The studies were conceived and designed by R.F. J.E.C. D.G. J.A.R. B.W. and P. Downie. Cell line generation by R.F. C.J. A.R. M.M. E.A.S.-C. S.Y.Y.L. A.H.P.L. N.F.S.S. M. Torchi, D.S.J. B. Day, P.G.E. J.I.F. M.V. E.H.R. J.A.R. B.W.S. B. Dumevska, L.E.L. M.D.D. D. Carvalho, A.D. E.F. L.C.S. V.B. P.B.S. D.E.C. D.S. M. Tsoli, V. Tyrrell, M.K. N.C. and P. Daniel. Biobanking/platform by N.N. M.Panday, N.Z. D.H. and C.D. Experiments performed by R.F. D.E.C. A.D. M.Pörksen, T.N. D.S. D.F. W.C.C. C.S. S.A. S.P. H.S. Y.Q. V.Tsui, N.C. M.L. G.B. and P. Daniel. Computational analyses performed by R.F. P. Daniel, and C.X.S. Writing, manuscript preparation by R.F. P. Daniel, and C.X.S. The authors declare no competing interests. We support inclusive, diverse, and equitable conduct of research. Publisher Copyright: © 2023 Elsevier Inc.
PY - 2023/4/10
Y1 - 2023/4/10
N2 - Pediatric solid and central nervous system tumors are the leading cause of cancer-related death among children. Identifying new targeted therapies necessitates the use of pediatric cancer models that faithfully recapitulate the patient's disease. However, the generation and characterization of pediatric cancer models has significantly lagged behind adult cancers, underscoring the urgent need to develop pediatric-focused cell line resources. Herein, we establish a single-site collection of 261 cell lines, including 224 pediatric cell lines representing 18 distinct extracranial and brain childhood tumor types. We subjected 182 cell lines to multi-omics analyses (DNA sequencing, RNA sequencing, DNA methylation), and in parallel performed pharmacological and genetic CRISPR-Cas9 loss-of-function screens to identify pediatric-specific treatment opportunities and biomarkers. Our work provides insight into specific pathway vulnerabilities in molecularly defined pediatric tumor classes and uncovers biomarker-linked therapeutic opportunities of clinical relevance. Cell line data and resources are provided in an open access portal.
AB - Pediatric solid and central nervous system tumors are the leading cause of cancer-related death among children. Identifying new targeted therapies necessitates the use of pediatric cancer models that faithfully recapitulate the patient's disease. However, the generation and characterization of pediatric cancer models has significantly lagged behind adult cancers, underscoring the urgent need to develop pediatric-focused cell line resources. Herein, we establish a single-site collection of 261 cell lines, including 224 pediatric cell lines representing 18 distinct extracranial and brain childhood tumor types. We subjected 182 cell lines to multi-omics analyses (DNA sequencing, RNA sequencing, DNA methylation), and in parallel performed pharmacological and genetic CRISPR-Cas9 loss-of-function screens to identify pediatric-specific treatment opportunities and biomarkers. Our work provides insight into specific pathway vulnerabilities in molecularly defined pediatric tumor classes and uncovers biomarker-linked therapeutic opportunities of clinical relevance. Cell line data and resources are provided in an open access portal.
KW - biomarker
KW - brain cancer
KW - cell line atlas
KW - CRISPR screens
KW - epigenetics
KW - machine learning
KW - multi-omics feature analysis
KW - pediatric cancers
KW - precision medicine
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85151831513&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2023.03.007
DO - 10.1016/j.ccell.2023.03.007
M3 - Article
C2 - 37001527
AN - SCOPUS:85151831513
SN - 1535-6108
VL - 41
SP - 660-677.e7
JO - Cancer Cell
JF - Cancer Cell
IS - 4
ER -